Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Tacrolimus, ATC L04AD02
Opportunity Score
Confidence: 50%
Complexity: medium
719 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation
AI Analysis Summary
This is an open-house model for non-exclusive pharmaceutical discount agreements on Tacrolimus (ATC L04AD02) with AOK Bayern. It is not a standard procurement procedure and is not subject to procurement law. Contracts are offered to all qualifying pharmaceutical companies on identical, non-negotiable terms. The contract period is from 01.08.2026 to 31.07.2028, with possible entry at any time until 03.06.2028. No estimated value is provided. Only one lot is identified.
Strengths
Documents available
Open procedure
Medium complexity
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
- Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit)
- Submission of signed contract and annex 'Festlegung der vertragsgegenständlichen Arzneimittel'
Buyer
Name
AOK Bayern - Die Gesundheitskasse
Location
München, DEU
Identifier
DE811695320
Lots (1)
Non-exclusive discount agreements for Tacrolimus (ATC L04AD02). Contracts are identical and non-negotiable. All eligible pharmaceutical companies may join. Contracts end 31.07.2028; entry possible until 03.06.2028.
Procurement Details
Publication
14 Jun 2026
Deadline
03 Jun 2028, 10:00
Procedure
open
Contract
supplies
Language
DEU
Publication #
409342-2026
Classification
Performance: Germany
Documents (2)
Opportunity Score
Confidence: 50%
Complexity: medium
719 days
Deadline
supplies
Contract
Deep Portfolio Analysis
- Company fit score
- Missing certificates
- Eligibility blockers
- Bid / No-Bid recommendation